Fig. 1.
G-CSF/plerixafor/busulfan-fludarabine conditioning in AML prior to allo-SCT. Clinical trial schema and time points of PB sample collection. G, G-CSF (10 μg/kg); P, plerixafor (160 or 240 μg/kg); Bu, busulfan (130 mg/m2); Flu, fludarabine (40 mg/m2); ATG, antithymocyte globulin (0.5–2 mg/kg, given to patients with unrelated donors); PB, peripheral blood.

G-CSF/plerixafor/busulfan-fludarabine conditioning in AML prior to allo-SCT. Clinical trial schema and time points of PB sample collection. G, G-CSF (10 μg/kg); P, plerixafor (160 or 240 μg/kg); Bu, busulfan (130 mg/m2); Flu, fludarabine (40 mg/m2); ATG, antithymocyte globulin (0.5–2 mg/kg, given to patients with unrelated donors); PB, peripheral blood.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal